$104.48
Value $182B
ABT and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$104.48
Value $182B
$272.70
Value $657B
Abbott Laboratories (ABT) has a market value of $182B and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, ABT moved -17.7% and JNJ +39.7%. The P/E is 38.6 for ABT and 40.8 for JNJ. Dividend yield: ABT 2.41%, JNJ 1.94%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$182B
JNJ$657B
JNJ is 3.6 times ABT
Revenue, 12 months
ABT$48.2B
JNJ$99.3B
JNJ is 2.1 times ABT
Net income, 12 months
ABT$4.7B
JNJ$16.1B
JNJ is 3.4 times ABT
Operating margin
ABT13.8%
JNJ–
ROIC
ABT6.3%
JNJ12.4%
6.1 points apart
P/E
ABT38.6
JNJ40.8
JNJ is 1.1 times ABT
Dividend yield
ABT2.4%
JNJ1.9%
0.5 points apart
5-year return
ABT-10.3%
JNJ+92.0%
102.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-10.3%
JNJ+92.0%
| Period | ABTWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -17.7%Price -19.6% | +39.7%Price +36.6% |
| 3 years since November 17, 2023 | +11.8%+3.8% a yearPrice +5.0% | +98.2%+25.6% a yearPrice +82.1% |
| 5 years since November 17, 2021 | -10.3%-2.1% a yearPrice -18.8% | +92.0%+13.9% a yearPrice +67.0% |
| 10 years since November 18, 2016 | +216.4%+12.2% a yearPrice +162.2% | +208.0%+11.9% a yearPrice +136.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesJNJJohnson & Johnson
| Price | $104.48 | $272.70 |
|---|---|---|
| Market value | $182B | $657B |
| Enterprise value (EV) | $208B | $685B |
| P/E | 38.6 | 40.8 |
| P/E, 5-year median | 33.7 | 21.9 |
| P/B | 3.6 | 8.1 |
| EV/EBIT | 31.4 | 38.6 |
| Free cash flow yield | 3.7% | 3.1% |
| Revenue, 12 months | $48.2B | $99.3B |
|---|---|---|
| Net income, 12 months | $4.7B | $16.1B |
| Free cash flow, 12 months | $6.8B | $20.6B |
| Earnings per share, 12 months | $2.69 | $6.59 |
| Revenue growth, year on year | 5.7% | 6.1% |
| Revenue growth a year, past | +5.1%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | +8.3%over 5 years | +14.9%over 5 years |
| Gross margin | 56.9% | 67.6% |
|---|---|---|
| Operating margin | 13.8% | – |
| Net margin | 9.8% | 16.2% |
| ROIC | 6.3% | 12.4% |
| ROE | 9.1% | 19.7% |
| Cash | $4.3B | $17.2B |
|---|---|---|
| Total debt | $31.2B | $44.7B |
| Net debt / EBITDA | 3.3 | 1.1 |
| Interest cover | 6.7× | 18.0× |
| Dividend yield | 2.4% | 1.9% |
|---|---|---|
| Dividend per share, 12 months | $2.52 | $5.28 |
| Dividend growth a year, past | +10.4%over 5 years | +5.3%over 5 years |
| Buyback yield | 0.5% | 0.9% |
| Shareholder yield | 2.9% | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($657B) is about 3.6 times Abbott Laboratories ($182B), at today's prices.
Since November 18, 2016, ABT's price moved +162.2% and JNJ's +136.4%. With dividends: ABT +216.4% (+12.2% a year), JNJ +208.0% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.41% for Abbott Laboratories and 1.94% for Johnson & Johnson. Over the last twelve months they paid $2.52 and $5.28 per share.
At today's price, the P/E is 38.6 for ABT and 40.8 for JNJ. The median of the last five years was 33.7 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 16.2% for Johnson & Johnson, and the operating margin 13.8% and –. Revenue was $48.2B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.